[Addiction in DSM V and ICD-11 state of the art].

Fortschritte der Neurologie · Psychiatrie Pub Date : 2009-09-01 Epub Date: 2009-07-30 DOI:10.1055/s-0028-1109590
O-M Lesch
{"title":"[Addiction in DSM V and ICD-11 state of the art].","authors":"O-M Lesch","doi":"10.1055/s-0028-1109590","DOIUrl":null,"url":null,"abstract":"<p><p>Diagnoses are made for identifying rather homogeneous groups of patients being thereby relevant for research and for therapy. Therefore diagnostic manuals, like the DSM-IV and the ICD-10 are subjected to changing knowledge derived from research on one hand and to changes of clinical necessities. The diagnosis of substance related disorders, published for DSM-IV in 1994 and for the ICD-10 in 1992, has proven of value for epidemiological research and economic validation. In spite of these advantages the concept has prove to be too broad and rather unspecific for research, specific therapeutic strategies and for defining an illness course. During the last 20 years research has yielded many criteria of interest, which never entered DSM IV or ICD-10, remaining therefore on the level of single items, which are nowadays additionally assigned to all patients (like e. g. early versus late onset) or on the level of typologies (like e. g. Lesch's typology) demanding different treatments. To give an example: acamprosate has lasting relapse preventing effects in Lesch types I and II, while naltrexone is effective in types III and IV. For rendering an expertise in Germany, the referring literature recommends to utilize Lesch's typology additionally to the ICD-10 diagnosis, especially when prognosis or therapeutic strategies are demanded. Since 1999 different expert groups strive for including new criteria into DSM IV and ICD-10. The revised manuals should include easily assignable items for severity of different arrays (time illness onset, co-morbidity, withdrawal symptoms, bridge symptoms and neurological sequela). Different therapy stages (e. g. withdrawal or relapse prevention) need a different weighting of individual symptoms (e. g. degree of intoxication, severity of withdrawal is needed for acute treatment, while an assignment of co-morbidity and personality factors is necessary for relapse prevention). This quantifier is rendered by Lesch's typology, which is available in the form of a computer programme, based on a decision tree (see also www.ausam.at - Typology according to Lesch). Non substance related disorders should enter other diagnostic categories, like e. g. impulse control disorders. A revised diagnostic classification suggests presently offered therapeutic strategies to follow up with necessary modifications. A tailor made therapy according to subgroups can result in better long term performance of therapies offered to persons suffering form substance related disorders.</p>","PeriodicalId":509563,"journal":{"name":"Fortschritte der Neurologie · Psychiatrie","volume":" ","pages":"507-12"},"PeriodicalIF":0.0000,"publicationDate":"2009-09-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://sci-hub-pdf.com/10.1055/s-0028-1109590","citationCount":"5","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Fortschritte der Neurologie · Psychiatrie","FirstCategoryId":"3","ListUrlMain":"https://doi.org/10.1055/s-0028-1109590","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"2009/7/30 0:00:00","PubModel":"Epub","JCR":"","JCRName":"","Score":null,"Total":0}
引用次数: 5

Abstract

Diagnoses are made for identifying rather homogeneous groups of patients being thereby relevant for research and for therapy. Therefore diagnostic manuals, like the DSM-IV and the ICD-10 are subjected to changing knowledge derived from research on one hand and to changes of clinical necessities. The diagnosis of substance related disorders, published for DSM-IV in 1994 and for the ICD-10 in 1992, has proven of value for epidemiological research and economic validation. In spite of these advantages the concept has prove to be too broad and rather unspecific for research, specific therapeutic strategies and for defining an illness course. During the last 20 years research has yielded many criteria of interest, which never entered DSM IV or ICD-10, remaining therefore on the level of single items, which are nowadays additionally assigned to all patients (like e. g. early versus late onset) or on the level of typologies (like e. g. Lesch's typology) demanding different treatments. To give an example: acamprosate has lasting relapse preventing effects in Lesch types I and II, while naltrexone is effective in types III and IV. For rendering an expertise in Germany, the referring literature recommends to utilize Lesch's typology additionally to the ICD-10 diagnosis, especially when prognosis or therapeutic strategies are demanded. Since 1999 different expert groups strive for including new criteria into DSM IV and ICD-10. The revised manuals should include easily assignable items for severity of different arrays (time illness onset, co-morbidity, withdrawal symptoms, bridge symptoms and neurological sequela). Different therapy stages (e. g. withdrawal or relapse prevention) need a different weighting of individual symptoms (e. g. degree of intoxication, severity of withdrawal is needed for acute treatment, while an assignment of co-morbidity and personality factors is necessary for relapse prevention). This quantifier is rendered by Lesch's typology, which is available in the form of a computer programme, based on a decision tree (see also www.ausam.at - Typology according to Lesch). Non substance related disorders should enter other diagnostic categories, like e. g. impulse control disorders. A revised diagnostic classification suggests presently offered therapeutic strategies to follow up with necessary modifications. A tailor made therapy according to subgroups can result in better long term performance of therapies offered to persons suffering form substance related disorders.

[DSM V和ICD-11的成瘾现状]。
诊断是为了确定相当同质的患者群体,从而与研究和治疗相关。因此,像DSM-IV和ICD-10这样的诊断手册一方面受到来自研究的知识变化的影响,另一方面也受到临床需求变化的影响。1994年出版的DSM-IV和1992年出版的ICD-10对物质相关疾病的诊断已被证明对流行病学研究和经济验证具有价值。尽管有这些优点,但事实证明,对于研究、具体的治疗策略和确定病程来说,这一概念过于宽泛,而且相当不具体。在过去的20年里,研究产生了许多感兴趣的标准,这些标准从未进入DSM IV或ICD-10,因此仍然停留在单个项目的水平上,这些项目现在额外分配给所有患者(如早发与晚发)或类型学水平(如Lesch's类型学),需要不同的治疗。举个例子:阿康prosate在Lesch I型和II型中具有持久的复发预防作用,而纳曲酮在III型和IV型中有效。为了在德国提供专业知识,参考文献建议在ICD-10诊断之外使用Lesch的类型,特别是在需要预后或治疗策略时。自1999年以来,不同的专家组努力将新标准纳入DSM IV和ICD-10。修订后的手册应包括根据不同症状(发病时间、合并症、戒断症状、过桥症状和神经系统后遗症)的严重程度易于分配的项目。不同的治疗阶段(如戒断或预防复发)需要对个别症状进行不同的加权(如急性治疗需要中毒程度、戒断的严重程度,而预防复发需要对合并症和人格因素进行分配)。这个量词由Lesch的类型学呈现,该类型学以计算机程序的形式提供,基于决策树(参见www.ausam.at - Lesch的类型学)。非物质相关障碍应纳入其他诊断类别,如冲动控制障碍。修订后的诊断分类建议目前提供的治疗策略进行必要的修改。根据亚组量身定制的治疗可以为物质相关障碍患者提供更好的长期治疗效果。
本文章由计算机程序翻译,如有差异,请以英文原文为准。
求助全文
约1分钟内获得全文 求助全文
来源期刊
自引率
0.00%
发文量
0
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
提示
您的信息不完整,为了账户安全,请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
确定
请完成安全验证×
copy
已复制链接
快去分享给好友吧!
我知道了
右上角分享
点击右上角分享
0
联系我们:info@booksci.cn Book学术提供免费学术资源搜索服务,方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。 Copyright © 2023 布克学术 All rights reserved.
京ICP备2023020795号-1
ghs 京公网安备 11010802042870号
Book学术文献互助
Book学术文献互助群
群 号:604180095
Book学术官方微信
小红书